Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

SHP099, SHP2 Phosphatase Inhibitor

SHP099, SHP2 Phosphatase Inhibitor

$139.00
A highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor.
Catalog No. Unit Price Qty
M60319-2s 2 mg solid $139.00

Details

Product Information
Molecular Weight: 388.72
Formula: C16H20Cl3N5
Purity: ≥98%
CAS#: 1801747-11-4
Solubility: DMSO up to 100 mM
Chemical Name: 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine hydrochloride
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with IC50 0.071 μM. It stabilizes SHP2 in an auto-inhibited conformation, concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signaling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models. SHP099’s activity provides evidence that pharmacological inhibition of SHP2 is a viable strategy to target RTK-driven cancers and presents a new chemical tool for further interrogation of the multifaceted cellular functions of SHP2 in development, tumorigenesis, RTK-driven drug resistance and immune-checkpoint modulation.

How to Use:


In vitro: SHP099 was used at 10 µM in vitro and cellular assays.
In vivo:
SHP099 was dosed orally to mouse tumor xenograft models at 75-100 mg/Kg once per day.

Reference:

  • 1. Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. (2016) Nature. 535(7610):148-52.


SHP099_spec.pdf   
SHP099_MSDS.pdf   


Products are for research use only. Not for human use.

Description

Details

Product Information
Molecular Weight: 388.72
Formula: C16H20Cl3N5
Purity: ≥98%
CAS#: 1801747-11-4
Solubility: DMSO up to 100 mM
Chemical Name: 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine hydrochloride
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

SHP099 is a highly potent, selective and orally bioavailable small-molecule SHP2 inhibitor with IC50 0.071 μM. It stabilizes SHP2 in an auto-inhibited conformation, concurrently binds to the interface of the N-terminal SH2, C-terminal SH2, and protein tyrosine phosphatase domains, thus inhibiting SHP2 activity through an allosteric mechanism. SHP099 suppresses RAS–ERK signaling to inhibit the proliferation of receptor-tyrosine-kinase-driven human cancer cells in vitro and is efficacious in mouse tumor xenograft models. SHP099’s activity provides evidence that pharmacological inhibition of SHP2 is a viable strategy to target RTK-driven cancers and presents a new chemical tool for further interrogation of the multifaceted cellular functions of SHP2 in development, tumorigenesis, RTK-driven drug resistance and immune-checkpoint modulation.

How to Use:


In vitro: SHP099 was used at 10 µM in vitro and cellular assays.
In vivo:
SHP099 was dosed orally to mouse tumor xenograft models at 75-100 mg/Kg once per day.

Reference:

  • 1. Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. (2016) Nature. 535(7610):148-52.


SHP099_spec.pdf   
SHP099_MSDS.pdf   


Products are for research use only. Not for human use.

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: